Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...

The use of short-term hormone therapy for menopause is not associated with long-term cognitive impact after 10 years.

Authors say findings show interplay between hormonal, lifestyle, and sociodemographic factors and cognitive health.

early biomarker for dementia as well as a potential target for therapy. Mild cognitive impairment is linked to blood vessel dysfunction in the brain's temporal lobes -- the seat of memory ...

CBT-E is a promising treatment for adolescents with eating disorders who did not fully recover from FBT or could not engage ...

Both amyloid and tau PET are considered appropriate for patients presenting with mild cognitive impairment (MCI ... eligibility for treatment with an approved amyloid-targeting therapy. "Amyloid and ...

Opioid-related neurocognitive symptoms among patients on long-term opioid therapy were most prevalent during the course of therapy.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

TAK-071 improves cognition in Parkinson’s but not gait variability; further studies needed for clinical applications.

Mild cognitive impairment is linked to blood vessel dysfunction ... early biomarker for dementia as well as a potential target for therapy. The research, involving scientists from multiple ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

New research published in Menopause, the journal of The Menopause Society, found a possible link between severe menopause symptoms (including hot flashes and depression) and cognitive function in ...